CORRECTION article

Front. Genet., 17 August 2022

Sec. Computational Genomics

Volume 13 - 2022 | https://doi.org/10.3389/fgene.2022.961153

Corrigendum: Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma

  • 1. Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China

  • 2. Department of Esophageal Surgery, Harbin Medical University Cancer Hospital, Harbin, China

  • 3. Department of Medicine II, University Hospital LMU Munich, Munich, Germany

In the published article, there was an error in Figure 2 as published. The second ROC curve in Figure 2B and the second KM curve in Figure 2C are same with the first ROC curve in Figure 2B and the first KM curve in Figure 2C, respectively. The corrected Figure 2 appears below.

FIGURE 2

In the published article, there was an error in Results, Immune-Related Signature and the Survival of Patients With Glioma, paragraph 1. This sentence previously stated: “In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.93 and 0.90”

The corrected sentence appears below:

“In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.94 and 0.93”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

glioma, bioinformatics signature, prognosis, immune enviroment, immunetherapy

Citation

Zhang S, Xiao X, Wang Y, Song T, Li C, Bao H, Liu Q, Sun G, Sun X, Su T, Fu T, Wang Y and Liang P (2022) Corrigendum: Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma. Front. Genet. 13:961153. doi: 10.3389/fgene.2022.961153

Received

04 June 2022

Accepted

11 July 2022

Published

17 August 2022

Volume

13 - 2022

Edited and reviewed by

Richard D. Emes, University of Nottingham, United Kingdom

Updates

Copyright

*Correspondence: Peng Liang,

†These authors have contributed equally to this work and share first authorship

This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics